NIRAMAI Health Analytix Company

Breast Cancer is the leading type of cancer in women. According to WHO, one in every 8 women in US is at the risk of developing a breast abnormality in her life time. It is well-established that early diagnosis is very critical in saving a life of a cancer patient. They at NIRAMAI have developed a new cancer screening software that uses machine intelligence over thermography images to enable a low cost, easy to use, portable solution and requires minimal human supervision. Their solution can detect cancer at a much earlier stage than traditional diagnostic methods and self-examination and can therefore improve survival rates. Their method of breast cancer screening can detect tumors 5 times smaller than what clinical exam can detect, is non-contact, painless and free of any radiation, apart from being low-cost, and universally accessible. With their solution, women of all age groups can undergo frequent screening without any side-effects.
Technology: Biomarkers of Female Cancers
Industry: Data processing
Headquarters: Bangalore, Karnataka, India
Founded Date: 2016-01-01
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 9
Total Funding: 6050000
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-06-29
Last Funding Type: Grant

Visit Website
Register and Claim Ownership